Comments
Loading...

AbCellera Biologics

ABCLNASDAQ
$2.97
0.082.69%
At close: Jul 19, 5:10 PM EDT
$3.05
0.082.69%
After Hours: Jul 19, 5:10 PM EDT
15 minutes delayed
Consensus Rating1
Outperform
Highest Price Target1
$32.00
Lowest Price Target1
$5.00
Consensus Price Target1
$21.67

AbCellera Biologics (NASDAQ:ABCL) Stock, Analyst Ratings, Price Targets, Forecasts

AbCellera Biologics Inc has a consensus price target of $21.67 based on the ratings of 11 analysts. The high is $32 issued by BMO Capital on February 22, 2023. The low is $5 issued by Keybanc on July 11, 2024. The 3 most-recent analyst ratings were released by Keybanc, Keybanc, and Stifel on July 11, 2024, May 8, 2024, and February 21, 2024, respectively. With an average price target of $9.67 between Keybanc, Keybanc, and Stifel, there's an implied 216.94% upside for AbCellera Biologics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Feb
1
May
1
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.4
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Keybanc
Stifel
Piper Sandler
Goldman Sachs
Credit Suisse

1calculated from analyst ratings

Analyst Ratings for AbCellera Biologics

Buy NowGet Alert
07/11/2024Buy Now63.93%Keybanc
Scott Schoenhaus
$7 → $5MaintainsOverweightGet Alert
05/08/2024Buy Now129.51%Keybanc
Scott Schoenhaus
$8 → $7MaintainsOverweightGet Alert
02/22/2024Buy NowBenchmark
Robert Wasserman
UpgradeHold → BuyGet Alert
02/21/2024Buy Now457.38%Stifel
Stephen Willey
$21 → $17MaintainsBuyGet Alert
12/05/2023Buy Now96.72%Keybanc
Scott Schoenhaus
→ $6Initiates → OverweightGet Alert
10/13/2023Buy Now555.74%Piper Sandler
Allison Bratzel
→ $20Assumes → OverweightGet Alert
08/31/2023Buy Now293.44%Benchmark
Robert Wasserman
$20 → $12MaintainsBuyGet Alert
08/04/2023Buy Now686.89%Goldman Sachs
Andrea Tan
$27 → $24MaintainsBuyGet Alert
05/05/2023Buy Now818.03%Credit Suisse
Tiago Fauth
$34 → $28MaintainsOutperformGet Alert
02/28/2023Buy NowCowen & Co.
Steven Mah
Initiates → OutperformGet Alert
02/22/2023Buy Now949.18%BMO Capital
Gary Nachman
$40 → $32MaintainsOutperformGet Alert
02/22/2023Buy Now1014.75%Credit Suisse
Tiago Fauth
→ $34Reiterates → OutperformGet Alert
01/06/2023Buy Now490.16%SVB Leerink
Puneet Souda
$20 → $18MaintainsOutperformGet Alert
12/15/2022Buy Now883.61%Goldman Sachs
Andrea Tan
→ $30Initiates → BuyGet Alert
11/16/2022Buy Now850.82%Truist Securities
Robyn Karnauskas
→ $29Initiates → BuyGet Alert
11/09/2022Buy Now555.74%SVB Leerink
Puneet Souda
$13 → $20MaintainsOutperformGet Alert
08/10/2022Buy Now1014.75%Credit Suisse
Tiago Fauth
$40 → $34MaintainsOutperformGet Alert
07/26/2022Buy Now621.31%Piper Sandler
Do Kim
$21 → $22MaintainsOverweightGet Alert
05/11/2022Buy Now588.52%Piper Sandler
Do Kim
$28 → $21MaintainsOverweightGet Alert
05/11/2022Buy Now359.02%SVB Leerink
Puneet Souda
$20 → $14MaintainsOutperformGet Alert
02/25/2022Buy Now1211.48%Credit Suisse
Tiago Fauth
$39 → $40MaintainsOutperformGet Alert
02/25/2022Buy Now555.74%SVB Leerink
Puneet Souda
$25 → $20MaintainsOutperformGet Alert
12/21/2021Buy Now785.25%Benchmark
Robert Wasserman
→ $27Initiates → BuyGet Alert
11/19/2021Buy Now981.97%Piper Sandler
Do Kim
Initiates → OverweightGet Alert
08/13/2021Buy Now1506.56%Credit Suisse
Tiago Fauth
MaintainsOutperformGet Alert

FAQ

Q

What is the target price for AbCellera Biologics (ABCL) stock?

A

The latest price target for AbCellera Biologics (NASDAQ:ABCL) was reported by Keybanc on July 11, 2024. The analyst firm set a price target for $5.00 expecting ABCL to rise to within 12 months (a possible 63.93% upside). 8 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for AbCellera Biologics (ABCL)?

A

The latest analyst rating for AbCellera Biologics (NASDAQ:ABCL) was provided by Keybanc, and AbCellera Biologics maintained their overweight rating.

Q

When was the last upgrade for AbCellera Biologics (ABCL)?

A

The last upgrade for AbCellera Biologics Inc happened on February 22, 2024 when Benchmark raised their price target to N/A. Benchmark previously had a hold for AbCellera Biologics Inc.

Q

When was the last downgrade for AbCellera Biologics (ABCL)?

A

There is no last downgrade for AbCellera Biologics.

Q

When is the next analyst rating going to be posted or updated for AbCellera Biologics (ABCL)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbCellera Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbCellera Biologics was filed on July 11, 2024 so you should expect the next rating to be made available sometime around July 11, 2025.

Q

Is the Analyst Rating AbCellera Biologics (ABCL) correct?

A

While ratings are subjective and will change, the latest AbCellera Biologics (ABCL) rating was a maintained with a price target of $7.00 to $5.00. The current price AbCellera Biologics (ABCL) is trading at is $3.05, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch